Literature DB >> 35309827

Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging).

Roger G Owen1.   

Abstract

Entities:  

Year:  2019        PMID： 35309827      PMCID： PMC8925697          DOI： 10.1097/HS9.0000000000000243

Source DB:  PubMed          Journal:  Hemasphere        ISSN： 2572-9241


× No keyword cloud information.
  23 in total

1.  Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.

Authors:  S Ferrero; M Ladetto; D Drandi; F Cavallo; E Genuardi; M Urbano; S Caltagirone; M Grasso; F Rossini; T Guglielmelli; C Cangialosi; A M Liberati; V Callea; T Carovita; C Crippa; L De Rosa; F Pisani; A P Falcone; P Pregno; S Oliva; C Terragna; P Musto; R Passera; M Boccadoro; A Palumbo
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

2.  MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.

Authors:  Mikhail Roshal; Juan A Flores-Montero; Qi Gao; Maesa Koeber; Jessica Wardrope; Brian G M Durie; Ahmet Dogan; Alberto Orfao; Ola Landgren
Journal:  Blood Adv       Date:  2017-05-03

3.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

4.  Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Authors:  Maria Arroz; Neil Came; Pei Lin; Weina Chen; Constance Yuan; Anand Lagoo; Mariela Monreal; Ruth de Tute; Jo-Anne Vergilio; Andy C Rawstron; Bruno Paiva
Journal:  Cytometry B Clin Cytom       Date:  2015-06-02       Impact factor: 3.058

5.  Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Authors:  N Puig; M E Sarasquete; A Balanzategui; J Martínez; B Paiva; H García; S Fumero; C Jiménez; M Alcoceba; M C Chillón; E Sebastián; L Marín; M A Montalbán; M V Mateos; A Oriol; L Palomera; J de la Rubia; M B Vidriales; J Bladé; J J Lahuerta; M González; J F S Miguel; R García-Sanz
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528

6.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 7.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

8.  Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Authors:  Joaquin Martinez-Lopez; Juan J Lahuerta; François Pepin; Marcos González; Santiago Barrio; Rosa Ayala; Noemí Puig; María A Montalban; Bruno Paiva; Li Weng; Cristina Jiménez; María Sopena; Martin Moorhead; Teresa Cedena; Immaculada Rapado; María Victoria Mateos; Laura Rosiñol; Albert Oriol; María J Blanchard; Rafael Martínez; Joan Bladé; Jesús San Miguel; Malek Faham; Ramón García-Sanz
Journal:  Blood       Date:  2014-03-19       Impact factor: 22.113

9.  Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.

Authors:  Noemi Puig; Bruno Paiva; Marta Lasa; Leire Burgos; Jose J Perez; Juana Merino; Cristina Moreno; Maria-Belen Vidriales; Dolores Gómez Toboso; Maria-Teresa Cedena; Enrique M Ocio; Ramon Lecumberri; Alfonso García de Coca; Jorge Labrador; Maria-Esther Gonzalez; Luis Palomera; Mercedes Gironella; Valentin Cabañas; Maria Casanova; Albert Oriol; Isabel Krsnik; Albert Pérez-Montaña; Javier de la Rubia; Jose-Enrique de la Puerta; Felipe de Arriba; Felipe Prosper; Joaquin Martinez-Lopez; Quentin Lecrevisse; Javier Verde; Maria-Victoria Mateos; Juan-Jose Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Leukemia       Date:  2018-12-12       Impact factor: 11.528

10.  Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Authors:  Aurore Perrot; Valerie Lauwers-Cances; Jill Corre; Nelly Robillard; Cyrille Hulin; Marie-Lorraine Chretien; Thomas Dejoie; Sabrina Maheo; Anne-Marie Stoppa; Brigitte Pegourie; Lionel Karlin; Laurent Garderet; Bertrand Arnulf; Chantal Doyen; Nathalie Meuleman; Bruno Royer; Jean-Richard Eveillard; Lotfi Benboubker; Mamoun Dib; Olivier Decaux; Arnaud Jaccard; Karim Belhadj; Sabine Brechignac; Brigitte Kolb; Cecile Fohrer; Mohamad Mohty; Margaret Macro; Paul G Richardson; Victoria Carlton; Martin Moorhead; Tom Willis; Malek Faham; Kenneth C Anderson; Jean-Luc Harousseau; Xavier Leleu; Thierry Facon; Philippe Moreau; Michel Attal; Hervé Avet-Loiseau; Nikhil Munshi
Journal:  Blood       Date:  2018-09-24       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.